{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:09:37Z","timestamp":1785798577178,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T00:00:00Z","timestamp":1383955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40261-013-0151-4","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T10:28:55Z","timestamp":1383906535000},"page":"107-115","source":"Crossref","is-referenced-by-count":13,"title":["Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin\u00a0D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA"],"prefix":"10.1007","volume":"34","author":[{"given":"Amit","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,9]]},"reference":[{"key":"151_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the United States, 2010. Atlanta: US Department of Health and Human Services, CDC; 2010."},{"issue":"17","key":"151_CR2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038\u201347.","journal-title":"JAMA"},{"issue":"1","key":"151_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2458-8-117","volume":"8","author":"Q-L Zhang","year":"2008","unstructured":"Zhang Q-L, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Pub Health. 2008;8(1):117.","journal-title":"BMC Pub Health"},{"key":"151_CR4","doi-asserted-by":"crossref","unstructured":"St Peter WL. Chronic kidney disease and Medicare. J Manag Care Pharm. 2007;13(9 Suppl\u00a0D):S13\u20138.","DOI":"10.18553\/jmcp.2007.13.9-d.13"},{"issue":"4","key":"151_CR5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5414\/CNP67201","volume":"67","author":"GT Schumock","year":"2007","unstructured":"Schumock GT, Sprague SM. Clinical and economic burden of fractures in patients with renal osteodystrophy. Clin Nephrol. 2007;67(4):201\u20138.","journal-title":"Clin Nephrol"},{"issue":"3","key":"151_CR6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1523-1755.1999.00617.x","volume":"56","author":"M Rix","year":"1999","unstructured":"Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56(3):1084\u201393.","journal-title":"Kidney Int"},{"issue":"6","key":"151_CR7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1053\/ajkd.2000.19812","volume":"36","author":"M Coco","year":"2000","unstructured":"Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115\u201321.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"151_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000045533","volume":"84","author":"K Tsuchihashi","year":"2000","unstructured":"Tsuchihashi K, Takizawa H, Torii T, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin\u00a0D(3) analog administration in dialysis patients with end-stage renal disease. Nephron. 2000;84(1):13\u201320.","journal-title":"Nephron"},{"issue":"2","key":"151_CR9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.ajkd.2004.04.024","volume":"44","author":"DE Weiner","year":"2004","unstructured":"Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004;44(2):198\u2013206.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"151_CR10","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","volume":"16","author":"Y Slinin","year":"2005","unstructured":"Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788\u201393.","journal-title":"J Am Soc Nephrol"},{"key":"151_CR11","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(S3):S1\u2013202.","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"151_CR12","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation. Chapter 4.1: treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int. 2009;76(S113):S50\u201399.","DOI":"10.1038\/ki.2009.192"},{"issue":"6","key":"151_CR13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","volume":"40","author":"DW Coyne","year":"2002","unstructured":"Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin\u00a0D2 and 1,25-dihydroxy-vitamin\u00a0D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis. 2002;40(6):1283\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"151_CR14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP65335","volume":"65","author":"HE Joist","year":"2006","unstructured":"Joist HE, Ahya SN, Giles K, et al. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol. 2006;65(5):335\u201341.","journal-title":"Clin Nephrol"},{"issue":"5","key":"151_CR15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446\u201356.","journal-title":"N Engl J Med"},{"issue":"5","key":"151_CR16","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","volume":"19","author":"DG Dobrez","year":"2004","unstructured":"Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19(5):1174\u201381.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"151_CR17","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483\u201390.","journal-title":"Kidney Int"},{"issue":"15","key":"151_CR18","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"151_CR19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","volume":"78","author":"GA Block","year":"2010","unstructured":"Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010;78(6):578\u201389.","journal-title":"Kidney Int"},{"issue":"27","key":"151_CR20","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"19","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin\u00a0D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT\u00a0SHPT study. Nephrol Dial Transplant. 2012;19(27):3270\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"151_CR21","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3111\/13696998.2013.823092","volume":"16","author":"A Sharma","year":"2013","unstructured":"Sharma A, Ketteler M, Marshall TS, et al. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin\u00a0D in hemodialysis patients. J Med Econ. 2013;16(9):1129\u201336.","journal-title":"J Med Econ"},{"issue":"3","key":"151_CR22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3111\/13696998.2012.664799","volume":"15","author":"R Boer","year":"2012","unstructured":"Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ. 2012;15(3):509\u201320.","journal-title":"J Med Econ"},{"issue":"6","key":"151_CR23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1053\/j.ajkd.2010.07.012","volume":"56","author":"TI Shireman","year":"2010","unstructured":"Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin\u00a0D versus flexible-dose vitamin\u00a0D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis. 2010;56(6):1108\u201316.","journal-title":"Am J Kidney Dis"},{"issue":"27","key":"151_CR24","first-page":"1942","volume":"19","author":"M Ketteler","year":"2011","unstructured":"Ketteler M, Martin KJ, Cozzolino M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin\u00a0D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT\u00a0SHPT study. Nephrol Dial Transplant. 2011;19(27):1942\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"151_CR25","doi-asserted-by":"crossref","unstructured":"Schumock GT, Walton SM, Lee TA, et al. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin Pract. 2011;117(2):c151\u20139.","DOI":"10.1159\/000319781"},{"key":"151_CR26","unstructured":"United States Renal Data System. USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0151-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0151-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0151-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T21:59:48Z","timestamp":1647035988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0151-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,9]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0151-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,9]]}}}